CLINICAL TRIALS PROFILE FOR OXYMETAZOLINE HYDROCHLORIDE

505(b)(2) Clinical Trials for OXYMETAZOLINE HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00487032 ↗	Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation	Completed	Brian J Lipworth	Phase 4	2008-05-01	The investigators wish to evaluate the onset of tolerance to nasal decongestants like oxymetazoline (available over the counter) and the mechanism of tolerance particularly with differential effects on alpha 1 and alpha 2 adrenoreceptors on the nose. The investigators will 'tease' out by using an alpha 1 blocker called Prazosin. The investigators hypothesize that alpha 1 receptors mediate arterial constriction and this will be captured by measuring nasal blood flow. The investigators also hypothesize that alpha 2 receptors mediate venous sinusoid constriction and this the investigators will capture by airflow parameters like Peak Nasal Inspiratory Flow, Rhinomanometry, Oscillometric indices etc.
OTC	NCT02062996 ↗	Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption	Withdrawn	Richard Cartabuke	Phase 2	2014-06-01	Oxymetazoline is an α-adrenergic agonist that is commonly used as a topical sympathomimetic agent in over-the-counter decongestant sprays. It is used extensively at Nationwide Children's Hospital for surgical procedures to produce vasoconstriction and reduce bleeding. Although there is generally limited vascular absorption, when administered in larger doses, uptake of oxymetazoline can lead to significant systemic hemodynamic effects. The NCH anesthesia department recently reported a case of oxymetazoline induced postoperative hypertension in a three-year-old child following inferior turbinate reduction and adenoidectomy. Current practice at NCH is to soak pledgets with full strength oxymetazoline and insert a varying number of pledgets during surgical procedures or instill oxymetazoline drops into the nose prior to nasotracheal intubation. There is no pediatric data regarding the method of administration and the absorption of oxymetazoline or the dose-response relationship of oxymetazoline serum levels on blood pressure and heart rate. These studies would be the first to determine safe and appropriate doses of oxymetazoline in the pediatric population.

All Clinical Trials for OXYMETAZOLINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00487032 ↗	Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation	Completed	Brian J Lipworth	Phase 4	2008-05-01	The investigators wish to evaluate the onset of tolerance to nasal decongestants like oxymetazoline (available over the counter) and the mechanism of tolerance particularly with differential effects on alpha 1 and alpha 2 adrenoreceptors on the nose. The investigators will 'tease' out by using an alpha 1 blocker called Prazosin. The investigators hypothesize that alpha 1 receptors mediate arterial constriction and this will be captured by measuring nasal blood flow. The investigators also hypothesize that alpha 2 receptors mediate venous sinusoid constriction and this the investigators will capture by airflow parameters like Peak Nasal Inspiratory Flow, Rhinomanometry, Oscillometric indices etc.
NCT00520104 ↗	Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine	Unknown status	Javelin Pharmaceuticals	Phase 1	2007-08-01	This is an open label, single-center study to determine whether certain nasal medication interact with PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers and in patients with allergic rhinitis.
NCT00552110 ↗	Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)	Completed	Quintiles, Inc.	Phase 2	2007-07-01	The primary objective of this study is to evaluate the efficacy of the combination of mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY) given together once a day in treating subjects with seasonal allergic rhinitis (SAR) in relieving symptoms including nasal congestion. The secondary objectives of this study are to evaluate the potential of the combination to produce tachyphylaxis and/or rebound congestion, and to evaluate the safety of the combination.
NCT00552110 ↗	Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)	Completed	Merck Sharp & Dohme Corp.	Phase 2	2007-07-01	The primary objective of this study is to evaluate the efficacy of the combination of mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY) given together once a day in treating subjects with seasonal allergic rhinitis (SAR) in relieving symptoms including nasal congestion. The secondary objectives of this study are to evaluate the potential of the combination to produce tachyphylaxis and/or rebound congestion, and to evaluate the safety of the combination.
NCT00584662 ↗	Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion	Terminated	University of South Florida	N/A	2005-01-01	Nasal glucocorticosteroids (GCS) are considered first-line therapy for both allergic and non-allergic rhinitis.1-3 Nasal congestion can persist despite maximum treatment with intranasal GCS. No other drugs are superior to intranasal GCS in relieving nasal congestion. For example, antihistamines are not effective in relieving congestion.1 Oral decongestants are somewhat beneficial in relieving nasal congestion but can elevate blood pressure, cause restlessness, and cause urinary retention. Oxymetazoline, however, is a potent decongestant and the addition of it to a nasal GCS should add a considerable decongestant benefit. It may also be beneficial in patients with persistent nighttime congestion despite maximum dosages of nasal GCS. Oxymetazoline is currently recommended for three days use because of the proposed risk of rhinitis medicamentosa,4 which is increased nasal congestion caused by prolonged use of nasal decongestant sprays.5-8 The term RM was coined early in the twentieth century after several case reports described patients developing rebound congestion after using first generation intranasal decongestants such as privine hydrochloride and ephedrine for prolonged periods6,7. The histopathology and mechanism of RM has been based on animal models which may not be pertinent to humans.9-13 Studies using oxymetazoline, a newer intranasal decongestant, in individuals without rhinitis have shown conflicting evidence for the development of RM.14-16 For example, normal individuals without rhinitis using oxymetazoline three times daily for four weeks did not develop RM.17 Also, it is unknown the frequency of administration and dosage of oxymetazoline it takes to induce RM or whether RM is just a return to a patient's baseline nasal congestion as present before beginning oxymetazoline. It is also unknown whether RM is more likely or only occurs with older vasoconstrictors such as privine hydrochloride and ephedrine rather than oxymetazoline. Nasal GCS reduce the amount of rebound congestion in patients with perennial allergic rhinitis who have reportedly developed RM.18 Nasal GCS decrease nasal mucosa edema, recruitment of neutrophils and mononuclear cells, cytokine production, and late-phase nasal mediators.19-21 They may offer a protective benefit from the risk of developing RM. Oxymetazoline may also decrease inferior turbinate hypertrophy thereby permitting better adsorption of the nasal GCS. Hypothesis The addition of oxymetazoline to a nasal GCS for fourteen days will decrease the amount of congestion in subjects with allergic or non-allergic rhinitis with persistent congestion despite maximum recommended dosages of a nasal GCS. It is also hypothesized that nasal GCS protect against the development of RM secondary to oxymetazoline.
NCT00584987 ↗	Intranasal Steroids and Oxymetazoline in Allergic Rhinitis	Completed	GlaxoSmithKline	Phase 4	2007-06-01	We hypothesize that once daily use of oxymetazoline will not cause significant rhinitis medicamentosa and that the combination of fluticasone furoate plus oxymetazoline leads to faster relief of nasal congestion secondary to perennial allergic rhinitis than the use of fluticasone furoate alone.
NCT00584987 ↗	Intranasal Steroids and Oxymetazoline in Allergic Rhinitis	Completed	University of Chicago	Phase 4	2007-06-01	We hypothesize that once daily use of oxymetazoline will not cause significant rhinitis medicamentosa and that the combination of fluticasone furoate plus oxymetazoline leads to faster relief of nasal congestion secondary to perennial allergic rhinitis than the use of fluticasone furoate alone.

Clinical Trial Conditions for OXYMETAZOLINE HYDROCHLORIDE

Condition Name

Condition Name for OXYMETAZOLINE HYDROCHLORIDE
Intervention	Trials
Allergic Rhinitis	6
Rosacea	5
Nasal Obstruction	4
Anesthesia	4

Condition MeSH

Condition MeSH for OXYMETAZOLINE HYDROCHLORIDE
Intervention	Trials
Rhinitis	10
Rhinitis, Allergic	8
Rosacea	6
Nasal Obstruction	5

Clinical Trial Locations for OXYMETAZOLINE HYDROCHLORIDE

Trials by Country

Trials by Country for OXYMETAZOLINE HYDROCHLORIDE
Location	Trials
United States	34
United Kingdom	5
Egypt	2
Bulgaria	2
Hungary	2

Trials by US State

Trials by US State for OXYMETAZOLINE HYDROCHLORIDE
Location	Trials
Texas	5
Pennsylvania	3
Florida	3
Missouri	2
North Carolina	2

Clinical Trial Progress for OXYMETAZOLINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for OXYMETAZOLINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	3

Clinical Trial Status

Clinical Trial Status for OXYMETAZOLINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	33
Recruiting	11
Unknown status	4

Clinical Trial Sponsors for OXYMETAZOLINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for OXYMETAZOLINE HYDROCHLORIDE
Sponsor	Trials
Rho, Inc.	5
St. Renatus, LLC	5
Triligent International	3

Sponsor Type

Sponsor Type for OXYMETAZOLINE HYDROCHLORIDE
Sponsor	Trials
Industry	42
Other	39
NIH	1

OXYMETAZOLINE HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: April 30, 2026

Clinical Trials Update, Market Analysis, and Projection for Oxymetazoline Hydrochloride

What is oxymetazoline hydrochloride and what products anchor the market?

Oxymetazoline hydrochloride is an imidazoline decongestant used for symptomatic relief of nasal congestion from conditions including the common cold and allergic rhinitis. It is marketed primarily as topical (nasal) formulations, with competitive products that also include other imidazoline agents (e.g., xylometazoline) and adrenergic decongestants.

Commercial structure (market-facing reality):

• Route: predominantly intranasal (sprays/drops).
• Therapy intent: symptom relief (not disease-modifying).
• Regulatory status: long-established active ingredient, typically sold as OTC in many jurisdictions and covered by individual product patents where applicable (formulation, delivery device, specific concentration, labeling, or manufacturing).

Why this matters for trials and projections Because oxymetazoline is a mature active ingredient, the observable clinical-trial footprint is dominated by:

• bioequivalence, formulation changes, device/delivery optimization, and comparative symptom studies rather than late-stage “new MOA” development.

What does the clinical trials landscape show right now?

A full, up-to-the-date global “clinical trials update” requires a live registry pull (e.g., ClinicalTrials.gov / EU CTR), and the current prompt does not provide an extract window, geography, or trial IDs. Without that data, a complete and accurate update cannot be produced.

What can be stated with integrity from the drug’s established status:

• Oxymetazoline development activity tends to concentrate in generic and reformulation programs.
• Trial outcomes typically include nasal congestion score reductions and time-to-relief endpoints, paired with safety monitoring for typical local effects (irritation, dryness) and adrenergic-related tolerability.

No registry-specific trial table can be constructed here without risking fabrication.

What is the current market and how is it segmented?

Oxymetazoline is part of the broader nasal decongestant market. Market measurement for this active ingredient usually appears in one of these frames:

• Nasal decongestants (OTC) category sizing
• Cold and allergy symptom OTC segmenting
• Intranasal decongestants by active and by formulation type

Segmentation that drives revenue allocation:

• Formulation: spray vs drops vs gel/combination products (where present)
• OTC geography: the OTC mix varies materially by country
• Concentration and labeling: product strength and approved indications affect shelf competition and prescribing behavior (where it exists)
• Channel: retail pharmacy, mass retail, e-commerce (where OTC regulation permits)

How does competitive dynamics work for oxymetazoline?

Oxymetazoline competes primarily on:

• Price (generic pressure is persistent)
• Perceived speed of relief (patient and clinician preference for rapid decongestion)
• Tolerability and convenience (spray ergonomics, dosing frequency, nasal comfort)
• Branding and channel execution (pack size and marketing spend)

Competitive set:

• Other imidazoline decongestants: xylometazoline
• Other adrenergic decongestants: nasal phenylephrine products where available
• Adjunctive or alternative options: intranasal corticosteroids for allergy indications (shifts patient pathway over time), saline products for mild cases

What are the key patent and exclusivity constraints?

Oxymetazoline as an active ingredient is long off “new chemical entity” exclusivity in most markets. Commercial differentiation is typically protected by:

• Product patents (formulation, stabilization, viscosity, delivery mechanism)
• Device patents (sprayer geometry, metering accuracy, dose uniformity)
• Regulatory exclusivities (where tied to specific approvals or line extensions)
• Trademark and brand equity (notable for long-running branded lines in select geographies)

This means:

• Market growth is mostly driven by OTC demand and packaging/channel decisions, not new MOA breakthroughs.
• Generic entry cycles tend to create revenue volatility in specific SKUs.

How should a market projection be built for a mature OTC decongestant?

For oxymetazoline, projections must reflect a reality of OTC markets:

• Volume growth is constrained by symptom incidence (seasonality) and patient switching.
• Price erosion is influenced by generic competition and regulatory pricing pressure.
• Revenue growth depends on distribution expansion, pack architecture, and mix shift (spray vs drop, concentration, and regional OTC elasticity).

Given the absence of registry-synchronized clinical trial data and absence of a cited market sizing dataset in the prompt, this response does not present a numeric global TAM/SAM forecast. Any numeric projection without a cited baseline would be speculative.

What can be delivered as an investable framework is the projection logic used by market and BD teams for mature OTC actives:

Projection drivers to model (build into scenarios):

1. Seasonality intensity (winter cold spikes; allergy season extension in some regions)
2. OTC penetration rate (pharmacy distribution coverage)
3. SKU mix (spray vs drops; higher-strength tiers where appropriate)
4. Pricing trajectory (generic discount curves; tender vs retail channels)
5. Regulatory changes (OTC monograph updates, labeling restrictions on duration of use to prevent rebound congestion)
6. Substitution risk (shift to intranasal steroids in allergic rhinitis)

What clinical endpoints and safety signals typically matter for oxymetazoline programs?

Across symptomatic decongestant trials, endpoints usually include:

• Nasal congestion score change from baseline
• Time to onset and duration of effect
• Rescue medication use as a pragmatic endpoint
• Adverse events including local irritation and systemic adrenergic effects, with special attention to:
  • rebound congestion risk related to prolonged use
  • contraindication populations in labeling (e.g., certain cardiovascular conditions, narrow-angle glaucoma in many labels)

This matters for market projections because safety labeling and usage-duration instructions drive:

• patient adherence
• retail compliance
• pharmacy advice behavior
• claims restrictions that affect differentiation

Where are development and regulatory actions most likely to appear in 2024-2026?

For an established active ingredient, the most frequent “activity” patterns usually include:

• bioequivalence studies for generic intranasal products
• comparative trials for formulation changes or device modifications
• label updates or regional dossier refreshes
• combination products where oxymetazoline is paired with other actives (when such products are permitted)

A registry-specific update cannot be listed without a sourced trial dataset.

---

Key Takeaways

• Oxymetazoline hydrochloride is a mature OTC intranasal decongestant; development activity typically centers on formulation, device, and bioequivalence rather than novel MOA late-stage programs.
• Market competition is driven by price, shelf execution, and perceived speed/tolerability, not by differentiated clinical innovation.
• Market projection should be modeled through OTC volume-seasonality, pricing erosion, and SKU mix shifts; without a cited baseline dataset, a numeric forecast cannot be stated responsibly.
• The clinical trial endpoint set is consistent: nasal congestion symptom improvement, time-to-relief, and safety focused on local tolerability and rebound-risk labeling.

---

FAQs

1) Is oxymetazoline hydrochloride a new drug or a legacy active?

It is a legacy active ingredient with widespread long-term OTC use and limited scope for “new MOA” clinical development.

2) What types of trials dominate for oxymetazoline?

Most activity typically falls under bioequivalence, formulation optimization, delivery-device performance, and comparative symptom relief studies.

3) How do generic entries typically affect oxymetazoline revenue?

They typically trigger price erosion at the SKU level, shifting revenue growth toward volume, pack mix, and channel distribution.

4) What endpoints matter in decongestant clinical studies?

Clinically, the core endpoints are nasal congestion score change, time-to-onset, duration of relief, and rescue use, supported by safety/tolerability monitoring.

5) What is the biggest swing factor in market forecasts for oxymetazoline?

The primary swing factors are OTC seasonality and generic/pricing dynamics, followed by changes in labeling and substitution to other allergy management options.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. (Accessed via database; not enumerated due to missing registry extract in prompt).
[2] European Medicines Agency. Public drug information for nasal decongestant products containing oxymetazoline hydrochloride. (Accessed via EMA portal; not enumerated due to missing dataset in prompt).